ACADIA Pharmaceuticals Inc. Research and Development Expense of Revenue

Research and Development Expense of Revenue of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Research and Development Expense of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Research and Development Expense of Revenue for the quarter ending December 30, 2020 was 7.7% (a -86.2% decrease compared to previous quarter)
  • Year-over-year quarterly Research and Development Expense of Revenue decreased by -90.45%
  • Annual Research and Development Expense of Revenue for 2020 was 60.29% (a -14.95% decrease from previous year)
  • Annual Research and Development Expense of Revenue for 2019 was 70.89% (a -15.23% decrease from previous year)
  • Annual Research and Development Expense of Revenue for 2018 was 83.63% (a -29.99% decrease from previous year)
  • Twelve month Research and Development Expense of Revenue ending December 30, 2020 was 48.34% (a -22.61% decrease compared to previous quarter)
  • Twelve month trailing Research and Development Expense of Revenue decreased by -31.94% year-over-year
Trailing Research and Development Expense of Revenue for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
48.34% 62.46% 65.4% 71.03%
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Research and Development Expense of Revenue of ACADIA Pharmaceuticals Inc.

Most recent Research and Development Expense of Revenueof ACAD including historical data for past 10 years.

Interactive Chart of Research and Development Expense of Revenue of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Research and Development Expense of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 7.7% 55.8% 58.4% 80.65% 60.29%
2019 58.5% 66.21% 80.91% 84.06% 70.89%
2018 80.88% 91.09% 81.65% 80.37% 83.63%
2017 99.12% 102.37% 112.16% 231.64% 119.45%
2016 252.62% 490.0% 21111.34% 569375.0% 572.87%
2015 120388.24% 48023.08% 1837900.0% 407375.0% 121096.72%
2014 38687.23% 113013.33% 49282.14% 38893.33% 50501.67%
2013 21421.62% 3022.5% 1576.94% 1062.35% 2333.8%
2012 1289.74% 126.51% 746.58% 1115.78% 383.0%
2011 752.38% 711.99% 938.04% 1014.25% 837.4%
2010 13.44% 215.78% 219.46% 48.84%

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.